Some studies [28,30] describe NPC as largely defined by NF-κB activation (40–90% of tumors), whereas other studies [18,32,33] report greater mutational diversity and lower NF-κB mutation prevalence (7–12%). Here, NFKB1 is linked to nasopharyngeal carcinoma.